SCHEMBL4669485

SCHEMBL4669485

CCOC(=O)N1CCC(Nc2cc(F)ccc2N)CC1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.57
KDM4E B2RXH2 2/20 0.57
MAPT P10636 2/20 0.57
GAA P10253 1/20 0.57
NOS2 P35228 5/20 0.53
NOS1 P29475 4/20 0.53
NOS3 P29474 2/20 0.53
HDAC1 Q13547 1/20 0.52
HDAC2 Q92769 1/20 0.52
LMNA P02545 2/20 0.51
HSD17B10 Q99714 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.48
CDK1 P06493 1/20 0.48
CDK4 P11802 1/20 0.48
CCND1 P24385 1/20 0.48
CDK2 P24941 1/20 0.48
MAP4K4 O95819 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
USP2 O75604 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4714159 0.91 ALDH1A1 (0.57) ALDH1A1KDM4EMAPTGAANOS2
SCHEMBL4635529 0.88 NOS2 (0.61) ALDH1A1KDM4EMAPTGAANOS2
SCHEMBL4635773 0.86 NOS2 (0.62) ALDH1A1KDM4EMAPTNOS2NOS1
SCHEMBL605250 0.85 LMNA (0.55) ALDH1A1KDM4EMAPTGAANOS2
SCHEMBL4635677 0.85 NOS2 (0.63) ALDH1A1KDM4EMAPTNOS2NOS1
SCHEMBL22716777 0.85 ALDH1A1 (0.57) ALDH1A1MAPTHDAC1HDAC2SMN1; SMN2
SCHEMBL4918724 0.83 NOS2 (0.62) ALDH1A1KDM4EMAPTNOS2NOS1
SCHEMBL13419731 0.82 NOS2 (0.54) ALDH1A1KDM4EMAPTGAANOS2
SCHEMBL4636292 0.82 MAPT (0.62) ALDH1A1KDM4EMAPTGAANOS2
SCHEMBL13351463 0.82 ALDH1A1 (0.55) ALDH1A1KDM4EMAPTGAANOS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8288413-B2 Benzimidazolones which have activity at M1 receptor GLAXO GROUP LIMITED (GB) 2012-10-16 US disclosed
US-8288413-B2 Benzimidazolones which have activity at M1 receptor GLAXO GROUP LIMITED (GB) 2012-10-16 US disclosed
US-8288413-B2 Benzimidazolones which have activity at M1 receptor GLAXO GROUP LIMITED (GB) 2012-10-16 US disclosed
US-20080306112-A1 Benzimidazolones Which Have Activity at M1 Receptor GLAXO GROUP LIMITED (GB) 2008-12-11 US disclosed
US-20080306112-A1 Benzimidazolones Which Have Activity at M1 Receptor GLAXO GROUP LIMITED (GB) 2008-12-11 US disclosed
US-20080306112-A1 Benzimidazolones Which Have Activity at M1 Receptor GLAXO GROUP LIMITED (GB) 2008-12-11 US disclosed
EP-1937670-A1 BENZIMIDAZOLONES WHICH HAVE ACTIVITY AT M1 RECEPTOR GLAXO GROUP LIMITED (GB) 2008-07-02 EP disclosed
WO-2007036711-A1 BENZIMIDAZOLONES WHICH HAVE ACTIVITY AT Ml RECEPTOR GLAXO GROUP LIMITED (GB) 2007-04-05 WO disclosed
WO-2007036711-A1 BENZIMIDAZOLONES WHICH HAVE ACTIVITY AT Ml RECEPTOR GLAXO GROUP LIMITED (GB) 2007-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306112-A1 Benzimidazolones Which Have Activity at M1 Receptor CHRM1, CHRM2, CHRM4 ALDH1A1 839/4885KDM4E 4335/4885MAPT 2221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.